Shivarov V. Immune-related adverse events in Hodgkin lymphoma treated with pembrolizumab or nivolumab: A disease-restricted US Food and Drug Administration Adverse Event Reporting System (FAERS) pharmacovigilance analysis. Br J Haematol 2026 Jul 29. doi: 10.1111/bjh.70724.
PMID: 42528255